Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur

NCT ID: NCT01374997

Last Updated: 2023-11-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-06-30
• Study Completion Date: 2013-05-14

Brief Summary

Fabry disease is a rare genetic disease characterized by an enzyme deficiency, called alpha-galactosidase A, which normally breaks down a lipid, is missing or does not function properly. As a result, the lipid accumulates in the body, this leads to multisystem impairment, including progressive renal failure.

Several studies have focused on the detection of this disease in end-stage renal failure patients, transplant or hemodialysis.

This study aims to diagnose the Fabry patients earlier, among men aged 18-60 years with a glomerular filtration rate estimated by MDRD between 60 and 15 ml/min/1, 73m2, or between 90 and 60 ml/min/1, 73m2 in association with proteinuria greater than 0.3 g / g or creatinine level greater than 0,5 g/l.

This screening will be conducted by a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper. If this assay was positive, confirmation of diagnosis of Fabry disease will done the standard method: macrodosage of leukocytic alpha-galactosidase A activity.

This multicenter prospective study, openly contacted in medical practice, with patient follow-up corresponding to the management of renal insufficiency, will be offered to all departments of nephrology and dialysis for adults in the Provence - Alpes - Côte d'Azur.

The objective of this study is to assess the prevalence of Fabry disease in the target population and to identify previously undiagnosed patients, enabling them to benefit from appropriate management of their disease, including whether need enzyme replacement therapy.

Conditions

Fabry Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

patients with Fabry disease

detection of this disease in end-stage renal failure patients, transplant or hemodialysis

Group Type: OTHER

micromethod from samples taken from blood spots on filter paper

Intervention Type: OTHER

a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper

Interventions

micromethod from samples taken from blood spots on filter paper

a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Men aged 18 to 60 years
• Glomerular filtration rate estimated by MDRD between 60 and 15 ml/min/1, 73m2, or between 90 and 60 ml/min/1,73m2 in association with proteinuria greater than 0.3 g/g creatinine or 0.5 g/l
• Patient able to understand the benefits and risks of the study
• Written Consent, informed, signed
• Patients insured under Social Security,

Exclusion Criteria

• Patients with a confirmed diagnosis of Fabry disease
• Patients belonging to a family in which a diagnosis of Fabry disease was confirmed
• Patients protected by law (under guardianship).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vincent ESNAULT, PU-PH

Role: PRINCIPAL_INVESTIGATOR

CHU NICE

Locations

Service de Néphrologie - Hôpital Pasteur

Nice, , France

Countries

France

Other Identifiers

10-PP-04

Identifier Type: -

Identifier Source: org_study_id